文献速递免疫规划慢病防控与筛查

在老龄小鼠中诱导有效的抗淀粉样β蛋白体液免疫应答

Induction of an effective anti-Amyloid-β humoral response in aged mice.
PubMed 文献 · Vaccine · 2021-07-20

该研究针对免疫衰老导致老年人对疫苗应答下降的问题,在老龄C57BL/6和5xFAD小鼠中采用幼年先用乙肝表面抗原(HBsAg)载体致敏、老龄再用Aβ1-11与HBsAg融合蛋白免疫的策略。结果显示该方案诱导的Aβ特异性抗体滴度显著高于直接免疫老龄未致敏小鼠,并更有效降低脑内Aβ水平、改变小胶质细胞表型,提示载体致敏可克服老年对自身抗原的体液免疫缺陷。

要点

  • 老龄小鼠抗Aβ抗体产生显著减少。
  • 幼年HBsAg载体致敏、老龄Aβ1-11-HBsAg免疫可提高抗体滴度。
  • 该策略更有效降低脑Aβ并改变小胶质细胞表型。

核心结论

  • 幼年用外源性抗原载体致敏可克服老年对自身抗原的体液免疫应答受损,为阿尔茨海默病免疫治疗提供路径。

研究设计与样本

  • 在老龄C57BL/6和5xFAD小鼠中比较幼年HBsAg致敏后老龄Aβ1-11-HBsAg免疫与老龄未致敏小鼠直接免疫的效果。

主要发现

  • 老龄C57BL/6和5xFAD小鼠抗Aβ抗体产生显著减少。
  • 幼年HBsAg致敏、老龄Aβ1-11-HBsAg免疫诱导的Aβ特异性抗体滴度显著高于老龄未致敏小鼠直接免疫。
  • 该疫苗策略更有效降低脑内Aβ水平并改变小胶质细胞表型。

临床怎么用

  • 提示针对老年人群的疫苗设计可考虑利用记忆性免疫,在年轻时期用载体致敏以增强老年期对自身抗原的抗体应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aging-related decline in immune functions, termed immunosenescence, is a primary cause of reduced protective responses to vaccines in the elderly, due to impaired induction of cellular and humoral responses to new antigens (Ag), especially if the response is T cell dependent. The result is a more severe morbidity following infections, more prolonged and frequent hospitalization, and a higher mortality rate than in the general population. Therefore, there is an increasing need to develop vaccination strategies that overcome immunosenescence, especially for aging-related diseases such as Alzheimer's disease (AD). Here we report a new vaccination strategy harnessing memory-based immunity, which is less affected by aging. We found that aged C57BL/6 and 5xFAD mice exhibit a dramatic reduction in anti-Amyloid-β (Aβ) antibody (Ab) production. We aimed to reverse this process by inducing memory response at a young age. To this end, young mice were primed with the vaccine carrier Hepatitis B surface antigen (HBsAg). At an advanced age, these mice were immunized with an Aβ1-11 fused to HBsAg. This vaccination scheme elicited a markedly higher Aβ-specific antibody titer than vaccinating aged unprimed mice with the same construct. Importantly, this vaccine strategy more efficiently reduced cerebral Aβ levels and altered microglial phenotype. Overall, we provide evidence that priming with an exogenous Ag carrier can overcome impaired humoral responses to self-antigens in the elderly, paving the route for a potent immunotherapy to AD.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Illouz T, Madar R, Hirsh T, et al. Induction of an effective anti-Amyloid-β humoral response in aged mice. Vaccine. 2021. PMID: 34294479. doi:10.1016/j.vaccine.2021.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。